Last reviewed · How we verify
Routine Lipid Management
At a glance
| Generic name | Routine Lipid Management |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Preoperative Fish Oil PN and Prognosis After Constipation Surgery
- Simulation-Based Team Training for Management of Local Anesthetic Systemic Toxicity (LAST) in Non-Anesthesiologist Surgical Residents (NA)
- Construction of a Comprehensive Health Management Platform for Patients With Cardiovascular-Kidney-Metabolic Syndrome (NA)
- Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study (NA)
- Seal, Stopping Eczema and Allergy Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine Lipid Management CI brief — competitive landscape report
- Routine Lipid Management updates RSS · CI watch RSS
- Amgen portfolio CI